Dallah posts 32% profit drop to SAR 100.1 mln in 2020

23/03/2021 Argaam Exclusive

View other reports

Dallah Healthcare Co. reported a drop of 32% in net profit before Zakat to SAR 100.1 million for 2020, from SAR 146.9 million a year earlier.

The profit decline was attributed to an increase in startup operating losses of Dr. Mohammed Alfagih Hospital, in which Dallah owns a 31.21% stake, as expected.

Financials (M)

Item	2019	2020	Change‬
Revenues	1,252.09	1,318.25	5.3 %
Gross Income	447.85	449.73	0.4 %
Operating Income	154.39	125.16	(18.9 %)
Net Income	146.92	132.00	(10.2 %)
Average Shares	90.00	90.00	-
EPS (Riyals)	1.63	1.47	(10.2 %)

The healthcare services provider allocated additional credit losses provisions, resulting from slowdown of economic cycles for some customers, in addition to the credit losses resulting from compilation of subsidiaries following the acquisitions.

Dallah reported higher general and administrative expenses, due to acquisitions and consolidation of subsidiaries’ financials. Zakat expenses also rose, on the consolidation of subsidiaries’ financials and the additional precautionary Zakat provision allocated by the company.

Current Quarter Comparison (M)

Compared With The

Item	Q4 2019	Q4 2020	Change‬
Revenues	343.60	405.30	18.0 %
Gross Income	127.34	143.57	12.7 %
Operating Income	64.09	40.26	(37.2 %)
Net Income	69.79	51.98	(25.5 %)
Average Shares	90.00	90.00	-
EPS (Riyals)	0.78	0.58	(25.5 %)

Item	Q3 2020	Q4 2020	Change‬
Revenues	350.79	405.30	15.5 %
Gross Income	132.62	143.57	8.3 %
Operating Income	50.51	40.26	(20.3 %)
Net Income	53.78	51.98	(3.3 %)
Average Shares	90.00	90.00	-
EPS (Riyals)	0.60	0.58	(3.3 %)

The fourth-quarter net profit plunged 71% YoY to SAR 20.1 million.

Shareholders’ equity, excluding minority interest, rose 15.6% YoY to SAR 1.759 billion in 2020.

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2011	129.97	-	49.69	-	30.24	-
Q2 2011	139.34	-	50.86	-	26.45	-
Q3 2011	115.44	10.2 %	37.37	1.3 %	16.67	(8.6 %)
Q4 2011	142.59	18.7 %	51.97	30.0 %	27.94	61.0 %
2011	527.34	11.6 %	189.89	11.8 %	101.30	14.0 %
Q1 2012	154.04	18.5 %	72.82	46.5 %	38.00	25.7 %
Q2 2012	161.32	15.8 %	73.73	45.0 %	38.16	44.2 %
Q3 2012	142.26	23.2 %	59.00	57.9 %	22.41	34.4 %
Q4 2012	179.43	25.8 %	81.51	56.9 %	32.18	15.2 %
2012	636.86	20.8 %	286.87	51.1 %	130.75	29.1 %
Q1 2013	183.73	19.3 %	84.40	15.9 %	38.39	1.0 %
Q2 2013	187.79	16.4 %	80.68	9.4 %	30.19	(20.9 %)
Q3 2013	167.08	17.4 %	66.67	13.0 %	21.95	(2.0 %)
Q4 2013	211.05	17.6 %	95.71	17.4 %	48.06	49.3 %
2013	749.65	17.7 %	327.45	14.1 %	137.53	5.2 %
Q1 2014	207.57	13.0 %	87.60	3.8 %	39.73	3.5 %
Q2 2014	219.45	16.9 %	93.78	16.2 %	33.46	10.8 %
Q3 2014	192.79	15.4 %	75.36	13.0 %	21.67	(1.3 %)
Q4 2014	240.08	13.8 %	103.54	8.2 %	50.24	4.5 %
2014	858.75	14.6 %	358.57	9.5 %	145.09	5.5 %
Q1 2015	240.40	15.8 %	102.13	16.6 %	39.67	(0.1 %)
Q2 2015	245.23	11.7 %	100.89	7.6 %	35.71	6.7 %
Q3 2015	223.93	16.2 %	87.92	16.7 %	26.37	21.7 %
Q4 2015	276.50	15.2 %	116.81	12.8 %	57.01	13.5 %
2015	985.44	14.8 %	407.14	13.5 %	160.78	10.8 %
Q1 2016	285.03	18.6 %	132.53	29.8 %	61.90	56.1 %
Q2 2016	288.35	17.6 %	129.78	28.6 %	59.34	66.2 %
Q3 2016	273.17	22.0 %	122.38	39.2 %	51.80	96.4 %
Q4 2016	316.24	14.4 %	151.01	29.3 %	57.96	1.7 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
Q1 2017	302.75	6.2 %	143.60	8.4 %	85.82	38.6 %
Q2 2017	288.20	0.0 %	130.48	0.5 %	70.86	19.4 %
Q3 2017	295.25	8.1 %	136.77	11.8 %	76.36	47.4 %
Q4 2017	325.87	3.0 %	148.23	(1.8 %)	74.95	29.3 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
Q1 2018	308.59	1.9 %	131.73	(8.3 %)	59.44	(30.7 %)
Q2 2018	273.13	(5.2 %)	92.38	(29.2 %)	19.67	(72.2 %)
Q3 2018	280.94	(4.8 %)	101.37	(25.9 %)	33.44	(56.2 %)
Q4 2018	318.28	(2.3 %)	110.86	(25.2 %)	33.04	(55.9 %)
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
Q1 2019	321.15	4.1 %	120.26	(8.7 %)	41.24	(30.6 %)
Q2 2019	286.00	4.7 %	92.46	0.1 %	18.06	(8.2 %)
Q3 2019	301.34	7.3 %	107.78	6.3 %	30.99	(7.3 %)
Q4 2019	343.60	8.0 %	127.34	14.9 %	64.09	94.0 %
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
Q1 2020	314.61	(2.0 %)	105.76	(12.1 %)	26.42	(35.9 %)
Q2 2020	247.56	(13.4 %)	67.77	(26.7 %)	7.97	(55.9 %)
Q3 2020	350.79	16.4 %	132.62	23.0 %	50.51	63.0 %
Q4 2020	405.30	18.0 %	143.57	12.7 %	40.26	(37.2 %)
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2011	527.34	11.6 %	189.89	11.8 %	101.30	14.0 %
2012	636.86	20.8 %	286.87	51.1 %	130.75	29.1 %
2013	749.65	17.7 %	327.45	14.1 %	137.53	5.2 %
2014	858.75	14.6 %	358.57	9.5 %	145.09	5.5 %
2015	985.44	14.8 %	407.14	13.5 %	160.78	10.8 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2011	35.25	-	0.39	-	35.25	0.39
Q2 2011	27.14	-	0.30	-	27.14	0.30
Q3 2011	15.49	(13.1 %)	0.17	-	15.49	0.17
Q4 2011	35.53	46.0 %	0.39	(3.38)	38.91	0.43
2011	113.40	20.0 %	1.26	(3.38)	116.79	1.30
Q1 2012	37.96	7.7 %	0.42	-	37.96	0.42
Q2 2012	37.09	36.7 %	0.41	-	37.09	0.41
Q3 2012	23.94	54.5 %	0.27	-	23.94	0.27
Q4 2012	34.37	(3.3 %)	0.38	-	34.37	0.38
2012	133.36	17.6 %	1.48	-	133.36	1.48
Q1 2013	39.04	2.8 %	0.43	-	39.04	0.43
Q2 2013	23.64	(36.3 %)	0.26	-	23.64	0.26
Q3 2013	21.84	(8.7 %)	0.24	-	21.84	0.24
Q4 2013	52.11	51.6 %	0.58	-	52.11	0.58
2013	136.63	2.5 %	1.52	-	136.63	1.52
Q1 2014	40.50	3.7 %	0.45	-	40.50	0.45
Q2 2014	34.33	45.2 %	0.38	-	34.33	0.38
Q3 2014	21.94	0.5 %	0.24	-	21.94	0.24
Q4 2014	50.35	(3.4 %)	0.56	-	50.35	0.56
2014	147.12	7.7 %	1.63	-	147.12	1.63
Q1 2015	47.82	18.1 %	0.53	13.75	34.07	0.38
Q2 2015	35.86	4.4 %	0.40	-	35.86	0.40
Q3 2015	26.78	22.1 %	0.30	-	26.78	0.30
Q4 2015	54.60	8.4 %	0.61	-	54.60	0.61
2015	165.06	12.2 %	1.83	13.75	151.31	1.68
Q1 2016	58.07	21.4 %	0.65	(2.02)	60.09	0.67
Q2 2016	54.14	51.0 %	0.60	(3.07)	57.21	0.64
Q3 2016	60.80	127.0 %	0.68	9.42	51.39	0.57
Q4 2016	51.71	(5.3 %)	0.57	(6.00)	57.71	0.64
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
Q1 2017	85.05	46.5 %	0.94	-	85.05	0.94
Q2 2017	69.99	29.3 %	0.78	-	69.99	0.78
Q3 2017	76.82	26.3 %	0.85	-	76.82	0.85
Q4 2017	63.12	22.1 %	0.70	(11.69)	74.81	0.83
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
Q1 2018	58.09	(31.7 %)	0.65	-	58.09	0.65
Q2 2018	18.73	(73.2 %)	0.21	-	18.73	0.21
Q3 2018	32.48	(57.7 %)	0.36	-	32.48	0.36
Q4 2018	32.47	(48.6 %)	0.36	-	32.47	0.36
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
Q1 2019	35.17	(39.5 %)	0.39	-	35.17	0.39
Q2 2019	15.35	(18.1 %)	0.17	-	15.35	0.17
Q3 2019	26.62	(18.1 %)	0.30	-	26.62	0.30
Q4 2019	69.79	115.0 %	0.78	13.39	56.41	0.63
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
Q1 2020	19.24	(45.3 %)	0.21	-	19.24	0.21
Q2 2020	6.99	(54.4 %)	0.08	-	6.99	0.08
Q3 2020	53.78	102.1 %	0.60	16.36	37.42	0.42
Q4 2020	51.98	(25.5 %)	0.58	34.87	17.11	0.19
2020	132.00	(10.2 %)	1.47	51.23	80.76	0.90

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2011	113.40	20.0 %	1.26	(3.38)	116.79	1.30
2012	133.36	17.6 %	1.48	-	133.36	1.48
2013	136.63	2.5 %	1.52	-	136.63	1.52
2014	147.12	7.7 %	1.63	-	147.12	1.63
2015	165.06	12.2 %	1.83	13.75	151.31	1.68
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
2020	132.00	(10.2 %)	1.47	51.23	80.76	0.90

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2011	-	-	-
Q2 2011	35.90 %	22.84 %	21.15 %
Q3 2011	35.24 %	22.42 %	20.24 %
Q4 2011	36.01 %	24.05 %	22.15 %
2011	36.01 %	24.05 %	22.15 %
Q1 2012	38.63 %	24.79 %	21.67 %
Q2 2012	41.14 %	25.88 %	22.58 %
Q3 2012	42.90 %	25.84 %	22.97 %
Q4 2012	45.06 %	25.05 %	20.93 %
2012	45.04 %	25.06 %	20.94 %
Q1 2013	44.79 %	24.18 %	20.16 %
Q2 2013	44.08 %	22.36 %	17.45 %
Q3 2013	43.63 %	21.80 %	16.56 %
Q4 2013	43.68 %	23.30 %	18.23 %
2013	43.68 %	23.16 %	18.23 %
Q1 2014	42.75 %	23.14 %	17.85 %
Q2 2014	42.69 %	22.94 %	18.48 %
Q3 2014	42.42 %	22.43 %	17.92 %
Q4 2014	41.90 %	22.11 %	17.11 %
2014	41.76 %	22.14 %	17.13 %
Q1 2015	41.98 %	21.38 %	15.76 %
Q2 2015	41.58 %	21.72 %	15.48 %
Q3 2015	41.54 %	21.77 %	15.49 %
Q4 2015	41.35 %	21.81 %	15.34 %
2015	41.32 %	22.03 %	15.35 %
Q1 2016	42.51 %	23.29 %	17.20 %
Q2 2016	43.49 %	24.24 %	18.50 %
Q3 2016	44.66 %	25.57 %	19.88 %
Q4 2016	46.07 %	24.94 %	19.47 %
2016	46.07 %	24.94 %	19.47 %
Q1 2017	46.32 %	26.38 %	21.29 %
Q2 2017	46.38 %	27.68 %	22.38 %
Q3 2017	46.73 %	29.19 %	24.08 %
Q4 2017	46.13 %	30.34 %	25.30 %
2017	46.13 %	30.34 %	25.30 %
Q1 2018	44.93 %	28.26 %	22.97 %
Q2 2018	42.33 %	24.50 %	18.99 %
Q3 2018	39.86 %	21.41 %	15.49 %
Q4 2018	36.95 %	18.60 %	12.00 %
2018	36.95 %	18.60 %	12.00 %
Q1 2019	35.60 %	17.66 %	9.96 %
Q2 2019	35.23 %	17.77 %	9.57 %
Q3 2019	35.16 %	17.58 %	8.93 %
Q4 2019	35.77 %	19.73 %	10.66 %
2019	35.77 %	19.73 %	10.66 %
Q1 2020	34.79 %	18.58 %	9.44 %
Q2 2020	33.85 %	18.13 %	9.05 %
Q3 2020	34.50 %	19.13 %	9.55 %
Q4 2020	34.12 %	16.71 %	6.13 %
2020	34.12 %	16.71 %	6.13 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2011	36.01 %	24.05 %	22.15 %
2012	45.04 %	25.06 %	20.94 %
2013	43.68 %	23.16 %	18.23 %
2014	41.76 %	22.14 %	17.13 %
2015	41.32 %	22.03 %	15.35 %
2016	46.07 %	24.94 %	19.47 %
2017	46.13 %	30.34 %	25.30 %
2018	36.95 %	18.60 %	12.00 %
2019	35.77 %	19.73 %	10.66 %
2020	34.12 %	16.71 %	6.13 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2011	38.23 %	26.96 %	27.12 %
Q2 2011	36.50 %	24.01 %	19.47 %
Q3 2011	32.37 %	19.85 %	13.42 %
Q4 2011	36.44 %	24.82 %	27.29 %
Q1 2012	47.27 %	29.16 %	24.64 %
Q2 2012	45.71 %	28.00 %	22.99 %
Q3 2012	41.48 %	20.83 %	16.83 %
Q4 2012	45.43 %	22.23 %	19.16 %
Q1 2013	45.94 %	25.32 %	21.25 %
Q2 2013	42.96 %	20.75 %	12.59 %
Q3 2013	39.90 %	18.63 %	13.07 %
Q4 2013	45.35 %	27.52 %	24.69 %
Q1 2014	42.20 %	24.47 %	19.51 %
Q2 2014	42.73 %	20.38 %	15.64 %
Q3 2014	39.09 %	16.97 %	11.38 %
Q4 2014	43.13 %	25.78 %	20.97 %
Q1 2015	42.48 %	21.43 %	14.17 %
Q2 2015	41.14 %	21.75 %	14.62 %
Q3 2015	39.26 %	17.88 %	11.96 %
Q4 2015	42.25 %	25.38 %	19.75 %
Q1 2016	46.50 %	26.86 %	21.08 %
Q2 2016	45.01 %	25.49 %	19.84 %
Q3 2016	44.80 %	24.50 %	18.81 %
Q4 2016	47.75 %	23.08 %	18.25 %
Q1 2017	47.43 %	32.36 %	28.09 %
Q2 2017	45.27 %	30.84 %	24.28 %
Q3 2017	46.32 %	30.89 %	26.02 %
Q4 2017	45.49 %	27.52 %	22.96 %
Q1 2018	42.69 %	24.11 %	18.82 %
Q2 2018	33.82 %	14.42 %	6.86 %
Q3 2018	36.08 %	18.15 %	11.56 %
Q4 2018	34.83 %	17.24 %	10.20 %
Q1 2019	37.45 %	20.42 %	10.95 %
Q2 2019	32.33 %	15.01 %	5.37 %
Q3 2019	35.77 %	17.35 %	8.83 %
Q4 2019	37.06 %	25.11 %	16.42 %
Q1 2020	33.62 %	15.88 %	6.12 %
Q2 2020	27.38 %	12.22 %	2.82 %
Q3 2020	37.81 %	21.04 %	10.67 %
Q4 2020	35.42 %	16.33 %	4.22 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2011	90.00	-	-	4.29
Q2 2011	90.00	1.16	1.16	4.63
Q3 2011	90.00	1.14	1.14	4.80
Q4 2011	90.00	1.26	1.30	5.21
Q1 2012	90.00	1.29	1.33	5.66
Q2 2012	90.00	1.40	1.44	6.04
Q3 2012	90.00	1.49	1.53	6.31
Q4 2012	90.00	1.48	1.48	12.40
Q1 2013	90.00	1.49	1.49	12.83
Q2 2013	90.00	1.34	1.34	12.37
Q3 2013	90.00	1.32	1.32	12.64
Q4 2013	90.00	1.52	1.52	13.22
Q1 2014	90.00	1.53	1.53	13.75
Q2 2014	90.00	1.65	1.65	13.36
Q3 2014	90.00	1.65	1.65	13.65
Q4 2014	90.00	1.63	1.63	14.15
Q1 2015	90.00	1.72	1.56	14.74
Q2 2015	90.00	1.73	1.58	14.63
Q3 2015	90.00	1.79	1.63	14.86
Q4 2015	90.00	1.83	1.68	15.48
Q1 2016	90.00	1.95	1.97	16.15
Q2 2016	90.00	2.15	2.21	15.76
Q3 2016	90.00	2.53	2.48	16.26
Q4 2016	90.00	2.50	2.52	16.85
Q1 2017	90.00	2.80	2.79	17.78
Q2 2017	90.00	2.97	2.93	17.24
Q3 2017	90.00	3.15	3.22	18.05
Q4 2017	90.00	3.28	3.41	18.80
Q1 2018	90.00	2.98	3.11	19.41
Q2 2018	90.00	2.41	2.54	17.98
Q3 2018	90.00	1.92	2.05	18.34
Q4 2018	90.00	1.58	1.58	17.79
Q1 2019	90.00	1.32	1.32	18.07
Q2 2019	90.00	1.28	1.28	16.24
Q3 2019	90.00	1.22	1.22	16.54
Q4 2019	90.00	1.63	1.48	16.91
Q1 2020	90.00	1.46	1.31	16.57
Q2 2020	90.00	1.36	1.21	16.65
Q3 2020	90.00	1.66	1.33	17.25
Q4 2020	90.00	1.47	0.90	19.94

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2011	90.00	1.26	1.30	5.21
2012	90.00	1.48	1.48	12.40
2013	90.00	1.52	1.52	13.22
2014	90.00	1.63	1.63	14.15
2015	90.00	1.83	1.68	15.48
2016	90.00	2.50	2.52	16.85
2017	90.00	3.28	3.41	18.80
2018	90.00	1.58	1.58	17.79
2019	90.00	1.63	1.48	16.91
2020	90.00	1.47	0.90	19.94

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2011	-	-	-
Q2 2011	-	-	-
Q3 2011	-	-	-
Q4 2011	-	-	-
Q1 2012	-	-	-
Q2 2012	-	-	-
Q3 2012	-	-	-
Q4 2012	25.26	25.26	3.02
Q1 2013	23.15	23.15	2.70
Q2 2013	26.26	26.26	2.85
Q3 2013	26.93	26.93	2.82
Q4 2013	26.15	26.15	3.00
Q1 2014	33.02	33.02	3.69
Q2 2014	33.91	33.91	4.19
Q3 2014	43.67	43.67	5.29
Q4 2014	45.25	45.25	5.23
Q1 2015	40.15	44.08	4.67
Q2 2015	45.84	50.27	5.43
Q3 2015	32.29	35.31	3.88
Q4 2015	27.26	29.73	3.23
Q1 2016	27.46	27.14	3.31
Q2 2016	28.54	27.81	3.89
Q3 2016	21.29	21.71	3.31
Q4 2016	27.05	26.85	4.01
Q1 2017	25.95	25.99	4.08
Q2 2017	26.81	27.16	4.62
Q3 2017	24.63	24.12	4.30
Q4 2017	21.93	21.10	3.82
Q1 2018	24.80	23.77	3.80
Q2 2018	28.42	26.97	3.81
Q3 2018	22.92	21.46	2.39
Q4 2018	25.39	25.39	2.25
Q1 2019	32.81	32.81	2.40
Q2 2019	34.90	34.90	2.76
Q3 2019	36.10	36.10	2.66
Q4 2019	25.93	28.53	2.50
Q1 2020	28.43	31.66	2.50
Q2 2020	31.13	34.94	2.55
Q3 2020	30.78	38.40	2.97
Q4 2020	35.71	58.36	2.63

Period	P/E	Adjusted P/E	Price/book
2011	-	-	-
2012	25.26	25.26	3.02
2013	26.15	26.15	3.00
2014	45.25	45.25	5.23
2015	27.26	29.73	3.23
2016	27.05	26.85	4.01
2017	21.93	21.10	3.82
2018	25.39	25.39	2.25
2019	25.93	28.53	2.50
2020	35.71	58.36	2.63

Business Segments (Million)

Compared With The

Period	Medical Services	Medicine and Pharmaceutical Products
Q1 2011	118.62	11.35
Q2 2011	132.76	6.58
Q3 2011	110.16	5.99
Q4 2011	134.16	7.73
Q1 2012	141.87	12.17
Q2 2012	148.75	12.57
Q3 2012	133.35	8.91
Q4 2012	163.03	16.20
Q1 2013	169.97	13.76
Q2 2013	168.24	19.56
Q3 2013	158.17	8.92
Q4 2013	192.80	18.25
Q1 2014	195.44	12.12
Q2 2014	201.76	17.69
Q3 2014	177.26	15.52
Q4 2014	223.36	16.72
Q1 2015	224.02	16.38
Q2 2015	228.38	16.85
Q3 2015	215.41	8.52
Q4 2015	257.40	18.49
Q1 2016	276.15	8.88
Q2 2016	277.42	10.93
Q3 2016	265.04	8.13
Q4 2016	307.51	8.73
Q1 2017	239.94	62.81
Q2 2017	229.31	58.90
Q3 2017	235.08	60.17
Q4 2017	241.44	84.43
Q1 2018	236.76	71.84
Q2 2018	205.73	67.39
Q3 2018	218.43	62.50
Q4 2018	228.74	89.55
Q1 2019	239.22	81.93
Q2 2019	210.95	75.06
Q3 2019	232.55	68.79
Q4 2019	259.40	84.20
Q1 2020	227.83	86.77
Q2 2020	166.96	80.60
Q3 2020	260.50	90.30
Q4 2020	309.74	95.55

Period	Medical Services	Medicine and Pharmaceutical Products
2011	495.70	31.64
2012	587.00	49.85
2013	689.17	60.48
2014	797.83	62.05
2015	925.20	60.24
2016	1,126.12	36.67
2017	945.78	266.30
2018	889.66	291.28
2019	942.12	309.97
2020	965.03	353.22

Analysts Estimates (Million)

Item	Q4 2020 (e)	Q4 2020 (a)	Change‬
Average	45.43	51.98	14.41 %

Estimates vs Actual (Million)

Item	Q4 2020 (e)	Q4 2020 (a)	Change
AlJazira Capital	50.40	51.98	3.1 %
OSOOL AND BAKHEET	45.90	51.98	13.2 %
Al Rajhi Capital	40.00	51.98	29.9 %

Financial Ratios

	Current
Market Cap (M Riyal)	15,062.26
Enterprise Value (EV) (M)	16,981.86
Shares Outstanding ((M))	97.68
EPS ( Riyal) (TTM)	4.82
Book Value (BV) ( Riyal)	34.96
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	31.98
P/E (TTM)	31.98
Price/book	4.41
Return on Average Assets (%) (TTM)	7.5
Return on Average Equity (%) (TTM)	14.3

Dallah Healthcare Co. (DALLAH HEALTH)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Dallah posts 32% profit drop to SAR 100.1 mln in 2020

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2020 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Dallah posts 32% profit drop to SAR 100.1 mln in 2020

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q4 2020

Revenue by Business Segment (Latest) 2020 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)